CD19 and neoplasm: In this study, we use patient data and an immunocompetent mouse model of CD19-directed CAR T-cell therapy targeting heterogeneous B-ALL tumors to identify novel tumor-intrinsic factors affecting CAR T-cell therapeutic outcomes.